Adjuvanter Einsatz von Trastuzumab (Herceptin®) in der klinischen Praxis außerhalb von klinischen Studien

Publisher： Karger

E-ISSN： 1661-3805|1|2|96-101

ISSN： 1661-3791

Source： Breast Care, Vol.1, Iss.2, 2006-05, pp. : 96-101

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Einsatz von Taxanen in der Therapie des Mammakarzinoms

By  

Breast Care, Vol. 1, Iss. 3, 2006-07 ,pp. : 189-193

Karger

Access to resources Recommend Favorite

Current Status of Financing and Reimbursement of Trastuzumab (Herceptin®) for Adjuvant and Advanced Therapy of Breast Cancer in Germany

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 86-94

Karger

Access to resources Recommend Favorite

Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 78-84

Karger

Access to resources Recommend Favorite

«Targeted Therapies» in der Behandlung von Brustkrebs

By  

Breast Care, Vol. 3, Iss. 3, 2008-06 ,pp. : 210-213

Karger

Access to resources Recommend Favorite

Trastuzumab as Intellectual, Medical and Economical Challenge

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 64-65

Karger

Access to resources Recommend Favorite